Phase 2 Lung Cancer Trial, Recruiting NCT04933903 Sponsor: Brown University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT04933903
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Note: The eligibility criteria document provided appears to list the same criteria under both "Inclusion" and "Exclusion" sections, which may be a formatting error in the source document. The exclusion criteria below are based on the standard opposite interpretations of the inclusion criteria, as is typical for this type of trial. Please confirm all criteria directly with the trial site.


Who might be able to join this trial:

  • You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue test
  • You are over 18 years old
  • You are generally active and able to care for yourself with little or no help (confirm with trial site)
  • Your lungs are strong enough to handle surgery to remove part of the lung, based on breathing tests
  • Your cancer is at a stage that can be surgically removed (stages IB to IIIB), and your surgical team believes a complete removal is possible
  • If cancer has spread to nearby lymph nodes, those nodes must not be growing into surrounding tissues
  • A chest surgeon has assessed you and agreed you are healthy enough to safely undergo major lung surgery
  • You have never had radiation treatment to the chest area before
  • Your blood, liver, and kidney test results are within acceptable ranges
  • You are able to understand and sign a consent form, or have someone who can do this on your behalf
  • You are not currently pregnant or breastfeeding
  • If you are a woman who could become pregnant, you are willing to use two forms of birth control, or abstain from sex, from the start of the study until 5 months after the last dose
  • If you are a woman, you are either past menopause or have a negative pregnancy test before starting the trial
  • You are willing and able to attend all required appointments and follow-up visits throughout the study
  • If you are a man, you agree to use contraception from your first dose until 7 months after your last dose

Who may not be able to join:

  • You do not have a confirmed diagnosis of non-small cell lung cancer
  • You are 18 years old or younger
  • Your general health or activity level is too limited to tolerate treatment (confirm with trial site)
  • Your lung function is not strong enough to safely handle lung surgery
  • Your cancer is not at a surgically removable stage, or a complete surgical removal is not considered possible
  • The cancer has spread to lymph nodes that are growing into surrounding structures
  • A chest surgeon has determined you are not healthy enough for major lung surgery, or you have serious other health conditions that make surgery too risky
  • You have had radiation treatment to the chest in the past
  • Your blood, liver, or kidney test results fall outside the acceptable ranges
  • You are unable to give consent and do not have someone who can do so on your behalf
  • You are currently pregnant or breastfeeding
  • If you are a woman who could become pregnant, you are unwilling to use required birth control methods
  • You are a man unwilling to use contraception during and after the study treatment period
  • You are unable or unwilling to attend required visits and follow all study procedures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christopher G Azzoli, MD, Brown University

Phone: 401-863-3000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Brown University
Registry
ClinicalTrials.gov
Start date
5 October 2021
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Patients with a Pathologic Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov